Clinical Trial Update: LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib [Phase 2]

View source ↗

Summary

Phase 2 study of LDK378 (alectinib) in adults with ALK-activated non-small cell lung cancer who were previously treated with chemotherapy and crizotinib has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LDK378 (Alectinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-05-08